Patents Assigned to Biocon Limited
-
Patent number: 7872095Abstract: An insulin compound coupled to a modifying moiety having a formula: —X—R1—Y-PAG-Z—R??(Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, either R1 or R2 is is a lower alkyl, optionally including a carbonyl group, and when R1 is a lower alkyl, R2 is a capping group, and PAG is a linear or branched carbon chain incorporating one or more alkalene glycol moieties, and optionally incorporating one or more additional moieties selected from the group consisting of —S—, —O—, —N—, and —C(O)—, and where the modifying moiety has a maximum number of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 heavy atoms.Type: GrantFiled: July 19, 2005Date of Patent: January 18, 2011Assignee: Biocon LimitedInventors: Balasingam Radhakrishnan, Diti Aggarwal, Michelle Ferro, Kenneth D. James, Navdeep B. Malkar, Mark A. Miller, Monica Puskas, Nnochiri N. Ekwuribe
-
Publication number: 20100317056Abstract: The present invention demonstrates the utility of carbonic acid amides such as urea or its derivatives, carbamates, carbodiimides & thiocarbamides as nitrogenous supplements in fermentation media for production of recombinant proteins to achieve enhanced bioconversion rates and peptides like insulin and insulin analogues, exendin and enzymes such as lipase using methanol inducible fungal expression systems such as Pichia.Type: ApplicationFiled: February 5, 2009Publication date: December 16, 2010Applicant: BIOCON LIMITEDInventors: Sanjay Tiwari, Mukesh Babuappa Patale, Saurabh Garg, Mayank Kumar Garg, Sulekha Joshi, Chittnalli Ramegowda Naveen Kumar, Bimal Kumar, Anuj Goel, Harish Iyer
-
Publication number: 20100317827Abstract: The invention relates, interalia, to the field of purification of peptides, notably cyclic or non-cyclic peptides their analogs or derivatives thereof. More particularly, the invention relates to a simplified and optimized purification process of cyclic peptides from a composition comprising the said peptide and at least one related impurity by chromatographic procedures enabling high yields, selectivity and purity of the desired end product. The improved process is particularly useful for the preparation of eptifibatide, exenatide, atosiban, nesiritide and their respective derivatives and analogs. The polypeptides are prepared in high purity of at least about 96%, and preferably at least about 99%.Type: ApplicationFiled: March 26, 2008Publication date: December 16, 2010Applicant: BIOCON LIMITEDInventors: Nitesh Dave, Krishnamurthy Venkatesan, Ramprabu Nagarajan, Harish Iyer
-
Publication number: 20100285143Abstract: The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations.Type: ApplicationFiled: October 16, 2008Publication date: November 11, 2010Applicant: BIOCON LIMITEDInventors: Anand Khedkar, Sharath, Kumar, Mallapura Rangappa, Ramesh Subramani, Nitesh Dave, Devesh Radhakrishnan, Sundaresh Shankar, Sudheer Chivukula, Ranjith Ramakrishna, Shanmugam, Thandava Murthy, Harish Venkatraman Pai, Nilanjan Sengupta, Ramakrishnan Melarkode, Harish Iyer
-
Publication number: 20100167342Abstract: The present invention relates to a method of producing a biologically active polypeptide having insulinotropic activity, the method comprising steps of: (a) transforming a genetically modified host cell that has protease gene knockout, with a polynucleotide vector encoding the polypeptide; and (b) growing the transformed host cell to produce the biologically active polypeptide; and a method of producing a biologically active polypeptide having an N-terminal recognition site His-Gly with insulinotropic activity, the method comprising steps of: (a) transforming a genetically modified Pichia pastoris that has protease gene STE13 knockout, with a polynucleotide vector encoding the polypeptide; and (b) growing the transformed Pichia pastoris to produce the biologically active polypeptide.Type: ApplicationFiled: June 20, 2007Publication date: July 1, 2010Applicant: BIOCON LIMITED,Inventors: Ramakrishnan Melarkode, Akundi Venkata Sriram, Kedarnath Nanjund Sastry, Lakshmi Prabha Varadarajalu, Shrikumar Suryanarayan
-
Patent number: 7713932Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.Type: GrantFiled: November 8, 2002Date of Patent: May 11, 2010Assignee: Biocon LimitedInventors: Nnochiri N. Ekwuribe, Balasingam Radhakrishnan
-
Patent number: 7704725Abstract: The present invention discloses a new strain of Streptomyces sp. BICC 7522, its variants or mutants and use of the strain for the production of macrolides, process of production and purification of microlides.Type: GrantFiled: April 12, 2004Date of Patent: April 27, 2010Assignee: Biocon LimitedInventors: Madhav Kulkarni, Surekha K. Prabhu, Madenahally Channabasappa Shivakumar, Prijyajit Sengupta, Sanjay Tiwari, Rakesh Mendhe, Nitin Patil, Laxmi Adhikary, Anand Khedkar, Ramakrishnan Melarkode, Ramavana Gururaja, Shrikumar Suryanarayan
-
Patent number: 7662773Abstract: Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, subcutaneous, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.Type: GrantFiled: November 26, 2003Date of Patent: February 16, 2010Assignee: Biocon LimitedInventors: Kenneth D. James, Balasingam Radhakrishnan, Navdeep B. Malkar, Mark A. Miller, Nnochiri N. Ekwuribe
-
Publication number: 20100029933Abstract: The present invention relates to a pure form of rapamycin with a total impurity content less than 1.2%; a process for recovery and purification of rapamycin comprising steps of (a) treating the fermentation broth, extracts or solutions containing rapamycin with water immiscible solvent and concentration; (b) addition of a water miscible solvent to effect separation of impurities present; (c) optionally, binding of the solvent containing the product from step (b) to an inert solid, washing the solid with a base and acid, followed by elution; (d) subjecting the elute from step (c) or the solvent containing the product from step (b) to silica gel chromatography; (e) crystallization of the product obtained from step (d); (f) subjecting a solution of the product from step (e) to hydrophobic interaction or reversed phase chromatography; and (g) re-crystallization to afford rapamycin in substantially pure form.Type: ApplicationFiled: December 26, 2006Publication date: February 4, 2010Applicant: Biocon LimitedInventors: Nitin Sopanrao Patil, Syed Idris Hussaini, Ashish Kumar Singh, Rakesh Bhaiyyaram Mendhe
-
Patent number: 7648962Abstract: Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.Type: GrantFiled: November 30, 2004Date of Patent: January 19, 2010Assignee: Biocon LimitedInventors: Kenneth D. James, Balasingham Radhakrishnan, Navdeep B. Malkar, Mark A. Miller, Nnochiri N. Ekwuribe
-
Patent number: 7645888Abstract: A novel process of the preparation of amorphous atorvastatin calcium starting from a compound of Formula (II).Type: GrantFiled: August 27, 2004Date of Patent: January 12, 2010Assignee: Biocon LimitedInventors: Sumithra Srinath, Joy Matthew, Tom Thomas Puthiaprampil, Sambasivam Ganesh
-
Patent number: 7635675Abstract: Fatty acid salt particles having a size distribution wherein the particles are from about 1 to about 1,000 microns in diameter, use of the particles in pharmaceutical compositions, as well as methods of making and using the particles and compositions.Type: GrantFiled: August 13, 2004Date of Patent: December 22, 2009Assignee: Biocon LimitedInventors: Foyeke Opawale, Richard Soltero
-
Patent number: 7625727Abstract: The present invention discloses the manufacture of MPA by fermentation under optimal fermentation parameters using a new strain of Penicillium arenicola.Type: GrantFiled: October 5, 2004Date of Patent: December 1, 2009Assignee: Biocon LimitedInventors: Surekha Prabhu, Pinakee Devi Sharma, Sanjay Tiwari, Ramakrishnan Melarkode, Ramavana Gururaja, Shrikumar Suryanarayan
-
Patent number: 7625995Abstract: The present invention provides a compound having a formula: where R1 is selected from the group consisting of alkyl, CH2(OC2H4)OCH3, and —(OC2H4)OCH3; n is 0-4; Olig is an oligomer having a formula: -L-O-PAGR.R2]q where L is a optional linker moiety selected from the group consisting of —CH2O—, —CH2OX—, —OX—, —C(O)—, —C(O)X, —NH—, —NHC(O)—, —XNHC(O)—, —NHC(O)X—, —C(O)NH—, —C(O)NHX—, and where X is alky1-6 or is not present, Y is N or O or is not present, and R3 is alkyl1-6; PAG is a linear or branched polyalkylene glycol moiety; R2 is an alkyl1-22 capping moiety if X is present or alkyl2-22 if X is not present; and q is a number from 1 to the maximum number of branches on PAG; and m is 1-5.Type: GrantFiled: February 26, 2008Date of Patent: December 1, 2009Assignee: Biocon LimitedInventors: Nnochiri Ekwuribe, Amy L. Odenbaugh
-
Patent number: 7611864Abstract: Methods for synthesizing proinsulin polypeptides are described that include a contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also described as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates are also described.Type: GrantFiled: September 30, 2004Date of Patent: November 3, 2009Assignee: Biocon LimitedInventors: Balasingam Radhakrishnan, Richard Soltero, Nnochiri N. Ekwuribe
-
Patent number: 7608584Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.Type: GrantFiled: November 8, 2002Date of Patent: October 27, 2009Assignee: Biocon LimitedInventors: Nnochiri N. Ekwuribe, Balasingam Radhakrishnan
-
Patent number: 7601688Abstract: The present invention provides compositions and methods for reducing hypoglycemic episodes experienced by a subject in need of treatment for diabetes mellitus, said method comprising orally administering an amount of an insulin polypeptide-oligomer conjugate to the subject, wherein: i) the amount of the insulin polypeptide-oligomer conjugate reduces the number and/or severity of hypoglycemic episodes experienced by the subject during a given time period when compared with the number and/or severity of hypoglycemic episodes that would have been experienced during a similar time period by the subject or by subjects in a control group parenterally administered insulin or an insulin analog in an amount that provides a substantially equivalent level of glycemic control; and ii) the oligomer of the insulin polypeptide-oligomer conjugate comprises a hydrophilic moiety and a lipophilic moiety.Type: GrantFiled: June 13, 2003Date of Patent: October 13, 2009Assignee: Biocon LimitedInventors: James Gordon Still, Gordana Kosutic
-
Patent number: 7557238Abstract: In one aspect, the present invention provides a novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate, a key intermediate for the preparation of HMG-CoA reductase inhibitor.Type: GrantFiled: September 18, 2003Date of Patent: July 7, 2009Assignee: Biocon LimitedInventors: Sumithra Srinath, Tom Thomas Puthiaparampil, Sambasivam Ganesh
-
Publication number: 20090171099Abstract: A novel process of the preparation of amorphous atorvastatin calcium starting from a compound of Formula (II).Type: ApplicationFiled: August 27, 2004Publication date: July 2, 2009Applicant: BIOCON LIMITEDInventors: Sumithra Srinath, Joy Mathew, Tom Thomas Puthiaprampil, Sambasivam Ganesh
-
Publication number: 20090082421Abstract: Crystalline polymorphic form B4 of Atorvastatin magnesium of FIG. 1 and processes for its preparation.Type: ApplicationFiled: June 15, 2006Publication date: March 26, 2009Applicant: BIOCON LIMITEDInventors: Joy Mathew, Manicka Ramamoorthy Sivakumar, Poornaprajna Acharya